Synthesis and application of188 Re-MN-16ET/Lipiodol in a hepatocellular carcinoma animal model

• Published in: Nuclear medicine and biology 2011, Vol.38 (7), p.1043-1052
• Main Authors: Tang, I-Chang, Luo, Tsai-Yueh, Liu, Show-Wen, Chan, Sun-Ho, Kung, Hong-Chang, Peng, Cheng-Liang, Lin, Wan-Yu, Chang, Yu, Lin, Wuu-Jyh
• Format: Article
• Language: English
• Subjects: Radiology
• ISSN: 0969-8051
• DOI: 10.1016/j.nucmedbio.2011.03.005

Abstract Introduction Hepatocellular carcinoma is the most common form of primary hepatic carcinoma. A new N2 S2 tetradentate ligand, N -[2-(triphenylmethyl)thioethyl]-3-aza-19-ethyloxycarbonyl-3-[2-(triphenylmethyl)thioethyl]octadecanoate (H3 MN-16ET), was introduced and labeled with188 Re to create188 Re-MN-16ET in the Lipiodol phase. The potential of188 Re-MN-16ET/Lipiodol for hepatoma therapy was evaluated in a hepatocellular carcinoma animal model of Sprague–Dawley rats implanted with the N1S1 cell line. Methods Synthesis of H3 MN-16ET was described, and characterization was identified by infrared, nuclear magnetic resonance and mass spectra. We compared the effects of transchelating agents (glucoheptonate or tartaric acid) and a reducing agent (stannous chloride) on the complexing of188 Re-perrhenate and H3 MN-16ET. Twenty-four rats implanted with hepatoma were injected with 3.7 MBq/0.1 ml of188 Re-MN-16ET/Lipiodol or188 Re-MN-16ET via transcatheter arterial embolization. Biodistribution experiments and single-photon emission computed tomography imaging were performed to investigate tumor accumulation. Results H3 MN-16ET was proved to easily conjugate with the Re isotope and showed good solubility in Lipiodol. The radiochemical purity of188 Re-MN-16ET/Lipiodol with 10 mg tartaric acid and stannous chloride was shown to be more than 90%. The major distribution sites of188 Re-MN-16ET in Sprague–Dawley rats were hepatoma and the liver. However, the radioactivity at the tumor site postadministered with188 Re-MN-16ET was quickly decreased from 9.15±0.23 (at 1 h) to 2.71%±0.18% of injected dose/g (at 48 h). The biodistribution and micro-single-photon emission computed tomography/computed tomography image data showed that188 Re-MN-16ET/Lipiodol was selectively retained at the tumor site, with 11.55±1.44, 13.16±1.46 and 10.67%±0.95% of injected dose/g at 1, 24 and 48 h postinjection, respectively. The radioactivity in normal liver tissue was high but significantly lower than that of the tumors. Conclusion H3 MN-16ET is a suitable tetradentate ligand for188 Re labeling. From the animal data, we suggest that188 Re-MN-16ET/Lipiodol has the potential to be a therapeutic radiopharmaceutical for hepatoma treatment.